Business
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Basal Cell Carcinoma (BCC) Using Novel Doxorubicin Containing Microneedle Arrays
About this update from Medicus Pharma Ltd.
[{"type":"text","content":"Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Basal Cell Carcinoma (BCC) Using Novel Doxorubicin Containing Microneedle Arrays (D-MNA)\nPhiladelphia, Pennsylvania--(Newsfile Corp. - June 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\" or the \"Company\") is pleased to announce the appointment of Andrew Smith as Chief Operating Officer.\nAndrew joins Medicus with over three decades of experience and is an accomplished C-suite professional with a successful track record as a leader in asset management and financial operations. Andrew, most recently, was the Chief Executive of SR Asset Management (SRAM) until its sale in 2024. Before joining SRAM in 2017, he was the Co-Head of Americas and Chief Operating Officer of Aberdeen Asset Management Inc. At Aberdeen, he held various roles including Chief Compliance Officer for their North American Closed End Funds as well as Chief Financial Officer and Chief Operating Officer for Aberdeen in the Americas. He currently sits on the board of HazelTree Fund Services and is an advisor to Code Registry.\nAndrew holds an Executive MBA from INSEAD in Fountainebleau and received an HND in Accounting from Glasgow College of Commerce, Scotland.\n\"We are delighted to welcome Andrew to the leadership team,\" stated Dr. Raza Bokhari, Executive Chairman and CEO. \"Andrew's experience and expertise is very relevant and timely, as we expand our business and clinical development operations with active engagements in three continents.\"\nThe Company also announced that its phase 2 clinical study to non-invasively treat BCC using novel D-MNA (SKNJCT-003) has now randomized more than fifty (50) of the 90 patients expected to be enrolled in the study.\nSKNJCT-003 Phase 2 clinical study is currently underway in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025, the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participant...